What is the main business of Qviti?

The main business activity of Qviti focuses on manufacture of irradiation, electromedical and electrotherapeutic equipment.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on March 10, 2016.

Where is the headquarters located?

The headquarters is located at: Plac Inwalidów 10, 01-552 Warszawa.

What is the share capital?

The share capital of the company is PLN 1,164,924 (approx. $314,674).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

In 2025, the company generated total revenue of $588,093, representing an increase of 35.4% compared to 2024.

No, the company recorded a net loss of $921,085 in 2025. For comparison, in 2024 the loss was $398,268, meaning the company increased its loss by 130.8%.

What is the main operating cost?

The largest operating cost category falls under external services. This category amounted to $607,872 in 2025, representing 53% of all operating expenses.

QvitiS.A.

Manufacture of irradiation, electromedical and electrotherapeutic equipment

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2016-03-10

Share capital

1 164 924,00 PLN

Activity description

Qviti is a company that specializes in advanced neuromodulation therapy, providing personalized treatments for neurological conditions such as aphasia, depression, post-stroke recovery, Alzheimer's, and chronic pain. Their medical-grade device integrates with external platforms and offers features like remote supervision and an advanced clinician interface for customized therapy protocols. The technology aims to improve quality of life by targeting specific neural patterns to enhance recovery and cognitive function.

Registered address

Plac Inwalidów 10, 01-552 Warszawa, Poland

Website

qviti.com

Phone

Electronic delivery address

AE:PL-66905-94073-HHIFU-19

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 588.09kMedianUSD 103.37kAverageUSD 1.78m

Net profit

This companyUSD -921.09kMedianUSD -472.34AverageUSD 120.51k

Operating costs

This companyUSD 1.14mMedianUSD 151.45kAverageUSD 1.57m

Assets

This companyUSD 2.42mMedianUSD 283.83kAverageUSD 2.08m

Industry

Bank accounts

Registered as a VAT taxpayer on 2008-12-15. Active

Bank Pekao SA
15 1240 6074 1978 0011 1342 0594
Bank Pekao SA
28 1240 6074 1111 0011 1342 0448

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication date	Event
Apr 5, 2016	Transformation registered

Public aid

8 public aid cases recorded, with a total value of $536,268.

Grant date	Purpose	Gross amount	Granting body
Jul 17, 2026	De minimis aid (in accordance with Commission Regulation 2023/2831)	$358$358	Prezes Zakładu Ubezpieczeń Społecznych
Nov 30, 2021	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$6,322$6,322	Prezes Zakładu Ubezpieczeń Społecznych
May 22, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$127.5K$127,522	Polski Fundusz Rozwoju S.A.

European Funds

Start	Project	EU co-financing	Programme
2019-02-01	836187 - Voic - revolutionary therapy of aphasia	$58,968$58,968	1.1.31 - Horizon 2020

Tenders

No recorded participation in tenders.

Authorized Representatives

Anna Kaczmarska — President of the Management Board

Manner of representation

If the management board is a multi-member management board, declarations of will on behalf of the company are made by the President of the Management Board or the Vice-President of the Management Board independently, or by two members of the management board acting jointly, or by one member of the management board acting jointly with a commercial proxy.

Supervisory board

Robert Aleksandrowicz — Supervisory Board Member

Mateusz Rosa Gawałkiewicz — Supervisory Board Member

Przemysław Piotr Mencel — Supervisory Board Member

Robert Mikulski — Supervisory Board Member

Beneficial owners

6 beneficial owners recorded in CRBR.

Person	Rights
Adam Aleksandrowicz (26)	Beneficjent podmiotu dominującego w stosunku do spółki będącej udziałowcem qviti s.a.
Michał Aleksandrowicz (28)	Beneficjent podmiotu dominującego w stosunku do spółki będącej udziałowcem qviti s.a.
Paweł Aleksandrowicz (36)	Beneficjent podmiotu dominującego w stosunku do spółki będącej udziałowcem qviti s.a.
Robert Aleksandrowicz (60)	Natural person exercising control on behalf of a supervisory body
Tomasz Józef Częścik (58)	Natural person exercising control on behalf of a supervisory body
Christos Kinanis (67)	Natural person exercising control on behalf of a supervisory body

Competitors

Name	Revenue	Website
Assistechsp. z o.o.	$1,803,586.75	assistech.eu
Silsense TechnologiesS.A.	$444,795.89	silsense.pl
Brain Opticssp. z o.o.	$103,370.62	brainoptics.eu
Inventmedsp. z o.o.	$73,620.90	inventmed.pl
ReadiyP.S.A.	$73,178.46	readiy.com.pl

Change history

Date	Event
2026-06-19	Share capital change (1,157,015.00 PLN → 1,164,924.00 PLN)
2025-11-14	Share capital change (1,100,000.00 PLN → 1,157,015.00 PLN)
2025-05-09	Name change (Neuro Device → Qviti)
2025-05-09	PKD change (Removed: 26, 32.5, 33.19, 33.20, 46.18, 47.99.Z, 70.2, 73; Added: 26.60.Z, 33.13.Z, 46.46.Z, 47.74.Z, 62, 77.39.Z)
2025-01-09	Share capital change (1,000,000.00 PLN → 1,100,000.00 PLN)

FAQ

Last updated: 2026-07-17